Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Elevated CRP Clear all

Conditions: Overweight (BMI > 25), Obesity (BMI>30), Hs-CRP
Interventions: Avocado, Control; Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 21 Years to 74 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Las Vegas, Nevada

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NP001, Placebo; Drug
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more

Conditions: Rheumatoid Arthritis
Interventions: M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Phoenix, Arizona • San Leandro, California • DeBary, Florida + 3 more

Conditions: Healthy Volunteers, C-Reactive Protein
Interventions: LY5625575, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Dallas, Texas

Conditions: C-Reactive Protein
Interventions: LY5625573, Midazolam, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Alamitos, California • Dallas, Texas

Conditions: Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
Interventions: Cardiopulmonary exercise test, Echocardiogram; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 110 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Type2 Diabetes, Glucose, High Blood
Interventions: Mediterranean Diet, Low-fat diet; Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases, Heart Diseases, Obesity
Interventions: Exercise; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions: Rosuvastatin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years and older
Enrollment: 17,802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 431
States / cities: Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more

Conditions: Crohn's Disease
Interventions: natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 63
States / cities: Oro Valley, Arizona • Tucson, Arizona • Anaheim, California + 54 more

Conditions: Inflammation
Interventions: Anatabine; Dietary Supplement
Lead sponsor: Roskamp Institute Inc.; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Sarasota, Florida • Flint, Michigan • Shelby, Michigan

Conditions: Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, C-Reactive Protein, High Sensitivity C-Reactive Protein, Hs-CRP, hsCRP
Interventions: TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG, Placebo; Drug · Other
Lead sponsor: Tourmaline Bio, Inc., a Novartis Company; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 38
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 32 more

Conditions: Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions: Clazakizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 16 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 10
States / cities: San Diego, California • West Palm Beach, Florida • Iowa City, Iowa + 7 more

Conditions: Metabolic Syndrome, Hyperlipidemia
Interventions: ProAlgaZyme; Drug
Lead sponsor: Health Enhancement Products, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Edina, Minnesota

Conditions: Heart Diseases, Diabetes, Obesity
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 50 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HDL Cholesterol
Interventions: Simvastatin, Atorvastatin 80 mg; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Volunteers, Elevated CRP
Interventions: MRT-8102, Placebo; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more

Conditions: Breast Cancer
Interventions: chemotherapy, endocrine therapy, DNA methylation analysis, protein analysis, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, conventional surgery, radiation therapy; Drug · Genetic · Other + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)

The TCF7L2 Gene: Dietary Prevention of T2DM

Effect of Exercise on Elevated C-reactive Protein Concentrations in Formerly Inactive Adults

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

Effect of Anatabine on Elevated Blood Levels of C-reactive Protein

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome

Fast Food Study: Assessment of the Effects of Fast-Food on Inflammatory Markers

Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery